Aspire Biopharma Holdings, Inc.
ASBP
$0.3366
-$0.0277-7.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.90M | -17.02M | -1.31M | -648.30K | -470.20K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.70M | 14.52M | -- | -- | -- |
| Change in Net Operating Assets | 261.20K | 642.30K | 1.01M | 130.70K | 184.10K |
| Cash from Operations | -2.95M | -1.86M | -303.40K | -517.60K | -286.10K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.30K | 38.30K | 38.30K | 38.30K | 38.30K |
| Cash from Investing | 38.30K | 38.30K | 38.30K | -37.60K | -37.60K |
| Total Debt Issued | 3.05M | 3.05M | 0.00 | 223.70K | 0.00 |
| Total Debt Repaid | -221.40K | -221.40K | -- | -- | -- |
| Issuance of Common Stock | 265.80K | 28.60K | 257.70K | 257.70K | 257.70K |
| Repurchase of Common Stock | -257.60K | -257.60K | -257.60K | -- | -- |
| Issuance of Preferred Stock | 257.60K | 257.60K | 257.60K | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 265.80K | -- | -- | -- |
| Cash from Financing | 3.09M | 3.12M | 257.70K | 481.40K | 257.70K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 186.60K | 1.30M | -7.60K | 1.90K | 9.80K |